Affidea Group has opened its first flagship neuraCare Centre in Athens, marking the planned rollout of a European network.
Flagship neuraCare Centre in Athens, Greece.Affidea Group
The centers take a multidisciplinary approach to integrated neurology care using unified standards, according to the company.
An early milestone will be the implementation of a clinical protocol study, it highlighted. Led by Prof. Marios Politis and in partnership with GE HealthCare, the study will evaluate the use of novel tracers in dementia diagnosis, toward a dedicated neurology module.
GE HealthCare technology will underpin the centers, Affidea noted. Key services including advanced diagnostics, involving neurological consultations, digital neurocognitive assessments, full pathology labs, and a diagnostic imaging suite equipped with PET/CT Omni Legend, the SIGNA Hero 3T MRI scanner, and SPECT/CT.
"We are building fully integrated pathways, from prevention and early detection to advanced treatments, clinical trials, and long-term monitoring, all delivered within a single, seamless patient journey," stated Affidea Group Executive Director Dr. Charles Niehaus. "NeuraCare is not just a new service line, it is a new model of care."
Planned locations include Warsaw and London, with Affidea neuraCare Athens the model for the network’s expansion.
In addition to advanced diagnostics, the centers will also provide therapies, including neuropsychology, neurological botox, digital and wearable-enabled monitoring, telehealth follow-up and continuous cognitive assessment, the company added.
The firm envisions the centers as clinical research hubs that provide direct patient access to academic, and pharmaceutical and industry-led trials, including dementia-focused tracer validation.
